Physician profile
Richard E Bock
NPI 1194793679
$5,337.75
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,628 · 2022: $2,264 · 2023: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $352 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $351.67 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $925.36 | 2021-2023 | |
| Novo Nordisk INC | $581.36 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $545.01 | 2021-2023 | Trelegy Ellipta |
| Amarin Pharma, INC. | $273.53 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $235.20 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $232.21 | 2021-2023 | |
| Abbott Laboratories | $232.03 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.29 | 2021-2023 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $196.77 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $171.98 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $165.07 | 2021 | |
| Amgen INC. | $157.11 | 2021-2023 | Repatha, Otezla |
| Pfizer INC. | $150.39 | 2021-2023 | |
| Astellas Pharma US INC | $148.74 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.83 | 2021-2023 | Xifaxan |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $108.64 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $105.44 | 2022-2023 | Gvoke Hypopen |
| Dexcom, INC. | $98.66 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $89.89 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $67.02 | 2021-2023 | Verquvo, Belsomra |
| Mylan Specialty L.P. | $56.85 | 2021-2022 | |
| Esperion Therapeutics, INC. | $56.05 | 2021 | |
| Sunovion Pharmaceuticals INC. | $51.31 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $46.91 | 2022 | |
| Lilly USA, LLC | $40.41 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.11 | 2022 | |
| Blue Earth Diagnostics | $29.73 | 2022 | |
| Clarus Therapeutics INC. | $28.85 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.43 | 2021 | |
| Boston Scientific Corporation | $16.85 | 2021 | |
| Axonics, INC. | $16.38 | 2021 | |
| Alkermes, INC. | $15.29 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.11 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.93 | 2021 | |
| Medtronic, INC. | $13.69 | 2021 | |
| Almatica Pharma LLC | $12.34 | 2022 | |
| Vanda Pharmaceuticals INC. | $11.72 | 2022 | |
| Coloplast Corp | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Bock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.